Plain-English translation of NCT02336815 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied , a new medication given alongside low-dose (a common steroid), in people with multiple myeloma that had stopped responding to multiple previous treatments. The trial included two parts: the first tested the medication in people with different levels of treatment resistance, and the second focused only on those with the most extensive prior treatment history. Researchers tracked how well the medication worked and how patients tolerated it.
Multiple myeloma is a blood cancer that becomes increasingly difficult to treat as patients receive more medications and their cancer becomes resistant to those treatments. This trial aimed to find a new option for people whose cancer no longer responds to the standard therapies available, offering hope to those with very limited treatment options remaining.
Participants received the medication ( 80 mg) plus low-dose twice per week on a repeating four-week schedule. The trial continued for up to about 13 months or until the cancer progressed, the participant experienced unacceptable side effects, or other stopping criteria were met. Throughout the study, participants underwent regular medical visits and tests to monitor how well the medication was working and how their body was tolerating it.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States